Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha® (evolocumab injection) for eligible patients following an acute coronary syndrome ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha(R) (evolocumab injection) for eligible ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results